Wesana Announces Participation at Upcoming Events in June 2021

NEXT STORY
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
PREV STORY
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cesca Announces Closing of $5.5 Million Public Offering

RANCHO CORDOVA, Calif., May 18, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

author_avatar
NASDAQ Market News

FitPro™ Go! Protein Shake Announced as Finalist in 6th Annual SupplySide West CPG Editor’s Choice Awards

Fairfield, CA, Sept. 14, 2017 (GLOBE NEWSWIRE) -- The FitPro Go! Protein Shake has ...

author_avatar
NASDAQ Market News

SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. ...

author_avatar
NASDAQ Market News